A detailed history of Geode Capital Management, LLC transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 79,716 shares of NVCT stock, worth $457,569. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,716
Previous 53,227 49.77%
Holding current value
$457,569
Previous $336,000 49.11%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$6.16 - $7.23 $163,172 - $191,515
26,489 Added 49.77%
79,716 $501,000
Q2 2024

Aug 09, 2024

SELL
$5.98 - $8.25 $486,179 - $670,733
-81,301 Reduced 60.43%
53,227 $336,000
Q1 2024

May 13, 2024

BUY
$6.69 - $11.0 $19,206 - $31,581
2,871 Added 2.18%
134,528 $1.1 Million
Q4 2023

Feb 13, 2024

BUY
$7.85 - $11.78 $15,652 - $23,489
1,994 Added 1.54%
131,657 $1.1 Million
Q3 2023

Nov 13, 2023

BUY
$12.89 - $16.29 $220,767 - $278,998
17,127 Added 15.22%
129,663 $1.67 Million
Q2 2023

Aug 11, 2023

BUY
$12.62 - $18.4 $978,226 - $1.43 Million
77,514 Added 221.33%
112,536 $1.8 Million
Q1 2023

May 15, 2023

BUY
$7.32 - $14.37 $26,747 - $52,507
3,654 Added 11.65%
35,022 $459,000
Q4 2022

Feb 13, 2023

SELL
$6.7 - $7.74 $489 - $565
-73 Reduced 0.23%
31,368 $235,000
Q3 2022

Nov 14, 2022

BUY
$7.09 - $13.0 $52,990 - $97,162
7,474 Added 31.18%
31,441 $222,000
Q2 2022

Aug 12, 2022

BUY
$7.02 - $20.44 $64,197 - $186,923
9,145 Added 61.7%
23,967 $268,000
Q1 2022

May 13, 2022

BUY
$3.25 - $9.1 $48,171 - $134,880
14,822 New
14,822 $109,000

Others Institutions Holding NVCT

About Nuvectis Pharma, Inc.


  • Ticker NVCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,642,500
  • Market Cap $84M
  • Description
  • Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...
More about NVCT
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.